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effects (probability of being in a specific 
health state) were compared for two 
surveillance strategies: (i) cystoscopy 
of the urinary bladder every 3 months 
(conventional arm), and (ii) semi-automated 
MA of voided urine samples to identify loss 
of heterozygosity every 3 months, with a 
control cystoscopy at 3, 12 and 24 months 
(test arm). Various sensitivity analyses were 
used to determine the sensitivity, specificity, 
and costs of MA of urine for which the test 
arm was as cost-effective as the 
conventional arm.
 
RESULTS
 
The probability of being without recurrence 
after 2 years of surveillance was similar 
(86.6% conventional arm vs 86.3% test arm) 
with currently available MA markers 
(sensitivity of 58% and specificity of 73%). 
However, the test arm led to higher costs 
(
 
€
 
4104 vs 
 
€
 
3433 per head). The test arm 
would be as effective and cost the same as 
the conventional arm if the sensitivity of 
the currently available MA markers was 
increased at 
 
≥
 
61%, had a specificity of 73%, 
and decreased the costs of the MA test per 
follow-up sample from 
 
€
 
158 to 
 
<€
 
70.
 
CONCLUSIONS
 
Over 2 years, surveillance in which 
cystoscopy is partly replaced by currently 
available urinary MA to reduce patient 
burden can only provide a cost-effective 
alternative to the conventional surveillance 
if the MA urine test had a slightly higher 
sensitivity and its costs could be reduced.
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OBJECTIVE
 
To determine how good microsatellite 
analysis (MA) markers in voided urine 
samples should be to make a surveillance 
procedure cost-effective in which 
cystoscopy is partly replaced by MA for 
patients with non-muscle-invasive 
urothelial carcinoma (NMI-UC).
PATIENTS AND METHODS
 
We constructed a semi-Markov model with a 
time horizon of 2 years, and a man aged 
65 years as reference case. Data were used 
from a randomized trial (including 448 
patients with NMI-UC from 10 hospitals), 
and from other data sources. The costs and 
 
INTRODUCTION
 
In the Western world bladder cancer is the 
fourth most common malignancy among 
men, after prostate, lung and colon cancers 
[1]. Histologically, 90–95% of bladder cancers 
in the western world are urothelial carcinoma 
(UC). UC not only originate from the urothelial 
lining of the bladder, but they can also occur 
in the pyelum, the ureters or the urethra. 
Clinically, a distinction is made between non-
muscle-invasive (NMI) and muscle-invasive 
(MI) UC. NMI-UC are generally treated 
surgically by a transurethral resection (TUR). 
Although these NMI-UC are generally rather 
indolent, their recurrence rate is high (up to 
75%). Close monitoring of patients with a 
NMI-UC is warranted as 10–20% of recurrent 
tumours can show progression to MI UC; the 
latter is a life-threatening disease, with a 5-
year survival of 
 
≈
 
50%, even after curative 
surgery (i.e. cystectomy). Surveillance of 
patients with NMI-UC is by regular 
cystoscopy (combined with cytological 
examination for high-risk NMI-UC). Although 
cystoscopy is considered as the reference 
standard for detecting tumour recurrences, a 
disadvantage of the method is its inability to 
detect recurrences in the upper urinary tract 
(UUT, pyelum, ureter). Moreover, cystoscopy is 
an invasive procedure, that can be associated 
with subsequent complaints of anxiety, 
dysuria and UTI, adversely influencing the 
quality of life of the patients [2–4]. Thus 
substantial efforts have been undertaken to 
design strategies that could reduce the 
frequency of cystoscopy in patients with 
NMI-UC [5,6]. One of these strategies is to 
replace cystoscopy partly by microsatellite 
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analysis (MA) to identify loss of 
heterozygosity in urine samples; published 
reports show that MA is a highly sensitive and 
specific marker for diagnosing and 
monitoring UC, especially in patients with 
low-stage and low-grade tumours [7]. Van der 
Aa 
 
et al.
 
 [8] showed, in a randomized 
controlled trial, that MA can be used to detect 
tumours earlier and to detect tumours in the 
UUT that might be missed by cystoscopy. 
However, the sensitivity (58%) and specificity 
of MA (73%) for detecting recurrences in the 
bladder were both worse than for cystoscopy 
(98% and 88%, respectively) [8].
In the present study we determined the 
requirements in terms of sensitivity, 
specificity and real costs of MA markers on 
voided urine samples to achieve cost-
effectiveness of a surveillance procedure of 
patients with NMI-UC whose cystoscopy is 
partly replaced by MA. We used data from the 
randomised controlled Cost-effectiveness of 
Follow-up of urinary Bladder Cancer (CEFUB) 
trial.
 
PATIENTS AND METHODS
 
We conducted the randomized controlled 
CEFUB trial (including 448 patients with NMI-
UC, recruited by 10 Dutch hospitals; 
registration ClinicalTrials.gov NCT00126958) 
to evaluate the efficacy of MA on voided urine 
for detecting tumour recurrences in the 
follow-up of patients. Patients included had 
a primary or recurrent NMI-UC (pTa, pT1, 
G1 or G2) of the urinary bladder, based on 
histopathological examination of the 
surgically removed tumour. Figure 1 shows 
the interventions in the conventional and test 
arm of the randomized study over 2 years. The 
conventional arm consisted of cystoscopy of 
the urinary bladder every 3 months. The test 
arm consisted of semi-automated MA of DNA 
(for 20 polymorphic microsatellite markers on 
10 chromosomes) extracted from voided urine 
samples from patients with a NMI-UC every 
3 months. A blood sample was taken as a 
control for the MA of the subsequent urine 
samples, and was used during the entire study 
period. A control cystoscopy was done at 3, 12 
and 24 months after TUR, and if the MA was 
positive. If a tumour recurrence was found by 
cystoscopy, irrespective of conventional or 
test arm, it was removed by TUR. If there was 
progression to MI-UC or G3 NMI-UC after 
adjuvant intravesical treatment, a cystectomy 
was considered. Additional radio-imaging was 
used to examine the UUT for the presence of 
UC, if the clinical performance was suspect or 
if the outcome of MA and cystoscopy were 
discordant, i.e. MA was positive but no 
tumour was detected by cystoscopy during 
two subsequent visits (i.e. a persistently 
positive MA). The UUT radio-imaging was not 
done immediately for a positive MA and 
negative cystoscopy, as previous studies 
showed that a positive MA test frequently 
antedates cystoscopically detectable 
recurrences [8,9]. Finally, 80 radio-imaging 
procedures showed seven tumours in the UUT 
(five in the test arm and two in the control 
arm). If there was suspected UC in the 
UUT, a unilateral nephroureterectomy was 
considered.
We constructed a semi-Markov decision 
model to assess costs and effects (probability 
of being in a specific health state) of both 
bladder cancer surveillance methods (i.e. the 
test and conventional arm). The model was 
implemented in DATA software (Version 
TreeAge PRO 2007, TreeAge Software, Boston, 
MA, USA). Figure 2 highlights the core of the 
surveillance model; monitoring patients with 
NMI-UC can prevent progression to MI-UC by 
detecting and treating recurrent tumours first 
(i.e. it is possible to prevent progression). 
Appendix 1 shows the underlying conceptual 
model; missing those patients with recurrent 
tumours can lead to cystectomy and a higher 
probability of death due to progressive 
tumours. Poor health states indicate dead, no 
bladder, progression (i.e. MI-UC or G3 NMI-
UC) and recurrent UC, and all other health 
states indicate ‘well’. Notably, after a detected 
recurrent UC, the patient will go back to 
the health state ‘well’ again. Transition 
probabilities for each 3 months were used to 
correspond with the follow-up times. The 
reference case was a man aged 65 years, and 
the time horizon was 2 years. To retain some 
 
FIG. 1. 
 
Interventions in the conventional and test arm of the randomized study, in which the plus sign 
indicates a positive MA test.
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FIG. 2. 
 
The core of the model for bladder cancer 
surveillance: monitoring patients with NMI-UC can 
prevent progression to MI-UC by detecting and 
treating recurrent tumours first (i.e. it is possible to 
prevent progression). This figure was used for the 
construction of the Markov model.
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memory in the Markov model some health 
states were constructed with a ‘sub-health’ 
state, indicating whether the MA was positive 
and the cystoscopy negative at the last visit of 
surveillance. When this was also the case in 
the subsequent visit, an IVU was assumed to 
be done.
Table 1 shows the variables used in the 
Markov model to provide insight into the 
current effects and costs of both strategies 
[10]. Data from the trial (448 patients) were 
used to determine the 3-month probabilities 
of recurrence (
 
P
 
rec
 
 
 
=
 
 .058) and progression 
after recurrence of NMI bladder cancer 
(
 
P
 
prog
 
 
 
=
 
 0.157) [8]. Also, the 3-month 
probabilities of undergoing a cystoscopy, 
sensitivity (58%) and specificity (73%) of MA, 
and sensitivity and specificity of cystoscopy in 
the bladder (98% and 88%, respectively) were 
determined by our trial data. Detailed, integral 
cost data of the MA analysis (blood and urine 
analysis) were obtained from the Department 
of Pathology of the Erasmus Medical Centre 
Rotterdam. Cost data for cystoscopy, 
IVU, TUR, cystectomy, and unilateral 
nephroureterectomy were obtained from the 
Department of Finance of the Academic 
Medical Centre Amsterdam. Unit prices were 
determined by following the microcosting 
method [11], which is based on 
comprehensive ‘bottom-up’ analyses and 
included costs of employment, material and 
equipment. A societal perspective was 
adopted. Costs of one cystoscopy procedure 
were calculated as 
 
€
 
168 per patient (the 
including personal costs were relatively 
low (
 
€
 
63.4 per patient) due to the short 
diagnostic time and efficient organization in 
the participating hospitals). We compared 
these costs with the determined unit prices of 
the Department of Finance of Erasmus 
Medical Centre Rotterdam. The costs were 
about the same. Confidentiality agreements 
did not allow us to give more detailed 
information. Costs of a single MA blood 
analysis and MA urine analysis were, 
respectively, 
 
€
 
357 and 
 
€
 
158. MA of the blood 
acted as reference value for MA urine analysis. 
Therefore, during 2 years of surveillance, costs 
of MA blood analysis were estimated only 
once (i.e. all costs were at the beginning of the 
surveillance). However, the costs of MA urine 
analysis were incurred at every follow-up.
We made the following assumptions in the 
present study: (i) progression takes place after 
recurrence; (ii) only one recurrence can take 
place at the same time; (iii) the health state 
‘recurrence in UUT after nephroureterectomy’ 
does not exist; this prevents a second possible 
nephroureterectomy in the model; (iv) only 
patients who had progression of the tumour 
at a specific time have a higher probability of 
death than the background mortality; (v) a 
cystoscopy never reveals a progressive 
recurrence, which originated in the UUT and 
invades the bladder; (vi) UUT imaging has a 
specificity of 100%; (vii) in case of progression 
to MI-UC the next step was a cystectomy; 
(viii) after cystectomy the surveillance stops; 
and (ix) if the IVU was positive the next step 
was a nephroureterectomy.
One-way sensitivity analyses were used 
to evaluate the effects of varying costs, 
recurrence rate, progression rate, sensitivity 
rates, and specificity rates. All point estimates 
 
TABLE 1 
 
The baseline assumptions of the Markov model
 
Description
Sensitivity/specificity,
% or 
 
P
 
 or costs, 
 
€
 
Note Source
Sensitivity MA, bladder 58 study
Sensitivity MA, UUT 58 study
Specificity MA, bladder 73 study
Specificity MA, UUT 73 study
Sensitivity cystoscopy, bladder 98 study
Sensitivity cystoscopy, UUT 0 study
Specificity cystoscopy, bladder 88 study
Specificity cystoscopy, UUT 100 study
Sensitivity IVU 60 http://www.guideline.gov
Specificity IVU 100 False positives not possible
 
3-month, 
 
P
 
Dead after progression 0.12 3-month risk year 1 Dutch comprehensive cancer centres
0.085 3-month risk year 2 Dutch comprehensive cancer centres
Progression after recurrence 0.157 study
Recurrence 0.058 Selection primary tumour 
 
+
 
counted for 3 recurrences
study
Recurrence UUT 0.1 Given there is a recurrence Dutch comprehensive cancer centres
Recurrence bladder after NU 0.12 [10]
 
Costs
 
MA blood analysis 357 Department of Pathology, Erasmus MC
MA urine analysis 158 Department of Pathology, Erasmus MC
Cystoscopy 168 Department of Finance, AMC
IVU 165 Department of Finance, AMC
TUR 1409 Department of Finance, AMC
Cystectomy 7997 Department of Finance, AMC
Nephroureterectomy 3333 Department of Finance, AMC
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of these variables were halved or doubled, 
except the point estimates of the sensitivity 
and specificity rates, which were increased 
and decreased based on previous reports 
[8,12].
Finally, by using a two-way sensitivity analysis 
between the sensitivity and specificity of MA, 
we determined a threshold line at which both 
surveillance strategies were equally effective. 
Various combinations of MA sensitivity, 
specificity, and costs of MA urine analysis 
were determined in which the test arm was as 
effective and cost the same as the 
conventional arm.
 
RESULTS
 
Table 2 shows the current costs and effects 
based on the Markov model for the 
conventional and test arm, respectively, for 
different follow-up samples. Over 2 years the 
total costs of surveillance were lower (
 
€
 
3433 
per head, 
 
€
 
1283 diagnostic and 
 
€
 
2150 
therapeutic costs) for the conventional arm, 
than for the test arm (
 
€
 
4104 per head, 
 
€
 
2347 
diagnostic and 
 
€
 
1757 therapeutic costs; 
column 3, stage 24 months). For the 
conventional arm the cost per head decreased 
by every subsequent stage (column 2), 
because the probability to be in health states 
‘Dead’ (column 4) or ‘No bladder’ (column 5) 
increased over the time. For the test arm the 
costs per head at stage 3 months were more 
than twice as high as the conventional arm. 
At stage 3 months not only was there MA 
urine analysis, but also a MA blood analysis 
and cystoscopy. Stages 12 and 24 months 
were more expensive than the conventional 
arm due to the control cystoscopy.
Over the 2 years there was a probability of 
6.1% of losing the bladder in the conventional 
arm and 7.9% in the test arm (see column 5, 
stage 24 months). The probability of having a 
progressive tumour in the bladder was very 
low, but higher (0.04%) in the test arm than 
the conventional arm (0.01%; column 7, stage 
24 months). However, the test arm resulted in 
better outcomes for UC originating in the UUT 
due to using IVU after twice-discordant 
outcomes between MA and cystoscopy in 
subsequent visits. Although the test arm 
detected tumours earlier and in the UUT, more 
tumours in the bladder were missed. 
Therefore, the current conventional and the 
test arm were similarly effective over the 
2 years (Fig. 3). Thus, the Markov model 
suggested, as expected, that the conventional 
arm dominated the test arm in terms of cost-
effectiveness. The conventional arm had 
lower costs and a slightly more patients in a 
good health state (86.6% vs 86.3%; Table 2, 
column 10, stage 24 months). Figure 3 also 
showed that (i) if patients had only MA with 
no control cystoscopy at stage 3, 12 and 
24 months, the probability of being in a poor 
health state would increase steeply; and (ii) if 
patients had only a cystoscopy at stage 3, 12 
and 24 months with no MA, fewer would be in 
a good health state than in the test arm.
 
TABLE 2 
 
Detailed overview of costs and effects in the conventional and test arms
 
Stage,
months
Costs, 
 
€
 
%
/stage Cumulative Dead
No
bladder
Progression
UUT
Progression
bladder
Recurrence
UUT
Recurrence
bladder Well
 
Conventional
 
3 451 451 0.37 0.80 0.09 0.02 0.49 0.09 98.15
6 447 897 0.75 1.61 0.25 0.02 0.89 0.09 96.40
9 440 1337 1.15 2.40 0.44 0.02 1.21 0.09 94.69
12 433 1769 1.57 3.18 0.66 0.02 1.48 0.08 93.01
15 426 2195 1.99 3.94 0.92 0.02 1.70 0.08 91.35
18 419 2615 2.43 4.68 1.19 0.02 1.87 0.08 89.73
21 412 3027 2.89 5.41 1.47 0.02 2.01 0.08 88.13
24 406 3433 3.37 6.12 1.74 0.01 2.12 0.08 86.57
 
Test
 
3 964 964 0.37 0.80 0.09 0.02 0.49 0.09 98.15
6 336 1300 0.75 1.27 0.21 0.36 0.76 1.91 94.75
9 355 1655 1.18 2.05 0.34 0.60 0.98 3.37 91.47
12 713 2367 1.66 3.81 0.46 0.04 1.11 0.11 92.81
15 323 2690 2.06 4.26 0.59 0.35 1.21 1.85 89.68
18 346 3036 2.50 5.02 0.70 0.58 1.27 3.22 86.72
21 366 3402 2.97 6.00 0.79 0.76 1.29 3.93 84.27
24 702 4104 3.45 7.94 0.86 0.04 1.30 0.11 86.29
 
FIG. 3. The probability (%) of being in a poor health 
state in either surveillance strategy (conventional or 
test arm) for different times of follow-up. Poor 
health states indicate dead, no bladder, progression 
and recurrence of UC.
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Table 3 shows various one-way sensitivity 
analyses of costs and effects for both 
surveillance arms over the 2 years. Changing 
the variables over plausible ranges did not 
make the test arm cheaper than the 
conventional arm. Only if the progression rate 
was halved (i.e. 0.079) was the probability of 
being ‘Well’ (i.e. being without a recurrence or 
progressive UC) larger in the test arm than 
the conventional arm (90.2% vs 89.5%, 
respectively) over the 2 years. This was also 
the case if the sensitivity of MA was increased 
to 70% (i.e. probability of being ‘Well’ was 
87.3% in the test arm vs 86.6% in the 
conventional arm). Obviously, changing the 
costs did not influence the health effect side.
Figure 4 shows that the test arm was equally 
effective as the conventional arm, if the MA 
had a sensitivity of 60.3% in combination 
with a specificity of 39.8%, or if the MA had a 
sensitivity of 62.8% in combination with a 
specificity of 100%, or all linear combinations 
of MA sensitivity and specificity in between. 
Table 4 shows that, for instance, if the 
sensitivity was increased to 61%, the 
specificity of MA remained at 73%, and the 
costs of MA urine tests will decrease to 
 
€
 
70, 
then the test arm is as effective and costs the 
same as the conventional arm.
 
DISCUSSION
 
Currently available MA markers are not 
sensitive enough (sensitivity of 58%) or 
specific (specificity of 73%) to use as a 
replacement for cystoscopy in the 
surveillance of bladder cancer. The probability 
of being without recurrence after 2 years of 
surveillance was similar for both surveillance 
strategies (86.6% conventional arm vs 86.3% 
test arm), but the test arm led to higher costs 
(
 
€
 
4104 vs 
 
€
 
3433 per head). The conventional 
arm hence dominated the test arm (less costs, 
similar effects). However, the test arm will be 
 
TABLE 3 
 
Sensitivity analysis of costs and effects for both surveillance arms over 2 years
 
Variable Variability
Cumulative costs, 
 
€
 
Difference
test – con
Probability, % of being ‘well’ Difference
test – conTest Conventional Test Conventional
Recurrence rate 0.029 3629 3053 576* 91.48 91.69
 
−
 
0.21
0.116 4954 4135 819* 77.04 77.08
 
−
 
0.04
Progression rate 0.079 3905 3276 629* 90.17 89.52 0.65†
0.314 4440 3731 709* 79.65 80.94
 
−
 
1.29
Costs cystoscopy, 
 
€
 
84 3745 2792 953* 86.29 89.57
 
−
 
3.28
336 4823 4716 107* 86.29 86.57
 
−
 
0.28
Costs MA blood, 
 
€
 
179 3926 3433 493* 86.29 89.57
 
−
 
3.28
714 4460 3433 1027* 86.29 86.57
 
−
 
0.28
Costs MA urine, 
 
€
 
79 3502 3433 69* 86.29 89.57
 
−
 
3.28
316 5308 3433 1875* 86.29 86.57
 
−
 
0.28
Sensitivity MA 0.29 4079 3433 646* 83.87 86.57
 
−
 
2.70
0.70 4111 3433 678* 87.27 86.57 0.70†
Specificity MA 0.69 4181 3433 748* 86.30 86.57
 
−
 
0.27
0.76 4048 3433 615* 86.28 86.57
 
−
 
0.29
Sensitivity cystoscopy 0.84 4093 3432 661* 84.63 85.31
 
−
 
0.68
0.98 4104 3433 671* 86.29 86.57
 
−
 
0.28
Specificity cystoscopy 0.79 4583 4327 256* 86.29 86.57
 
−
 
0.28
0.98 3572 2439 1133* 86.29 86.57
 
−
 
0.28
 
*Test arm is more expensive than conventional arm over 2 years; †Test arm is more effective than conventional arm over 2 years.
 
FIG. 4. 
 
The threshold analysis for surveillance 
strategies. Sensitivity and specificity combinations 
in the white area indicate that the conventional 
arm is more effective; sensitivity and specificity 
combinations in the light green area means that the 
test arm is more effective.
*  = current assumption for MA test (MA
       sensitivity 58%, MA specificity 73%)
x  = if MA-urine test has a sensitivity of 60.5%, a
       specificity of 47%, and will be free of charge,
       the test arm will be as effective and cost the
       same as the conventional arm
O = if MA-urine test has a sensitivity of 62.8%
       and a specificity of 100%, and will cost
       €130.5, the test arm will be as effective and
       cost the same as the conventional arm       
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TABLE 4 
 
Combinations of MA sensitivity, specificity, and costs of MA urine in which the test arm is as 
effective and costs the same as the conventional arm
 
Sensitivity MA, % Specificity MA, % Costs of MA urine, 
 
€
 
60.5 47 0.0
60.7 53 17.0
61.4 73 69.6
62.8 100 130.5
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as effective and cost the same as the 
conventional arm if the sensitivity of the 
current available MA markers increased to 
 
≥
 
61%, the specificity of MA remained at 73% 
and the costs of MA urine test per follow-up 
sample decreased from 
 
€
 
158 to 
 
<
 
€
 
70.
Lotan and Roehrborn [13] used a decision 
tree to evaluate the cost-effectiveness of 
substituting cystoscopy by other bladder 
tumour markers than MA markers. They 
showed that using a urine-based tumour 
marker alternating with cystoscopy is cost-
effective for a wide range of marker 
sensitivities, specificities and costs, a 20–80% 
yearly recurrence and a 2–40% yearly 
progression rate. Although the sensitivity and 
specificity of their tumour markers and our 
MA markers were almost the same as in the 
present study (respectively, 50% vs 58%, and 
70% vs 73%), the costs of diagnostic and 
therapeutic interventions used in both studies 
differed, especially for the costs of the tumour 
markers. Ignoring the inflation rate, the costs 
of the tumour markers were assumed as $50 
[13], in contrast to 
 
€
 
158 for our MA urine 
analysis and 
 
€
 
357 for the one-time MA blood 
analysis. It is plausible that genetic analysis 
(i.e. MA markers) are more expensive than 
urine-sediment diagnosis. However, for a fair 
comparison of costs we should use the same 
costing method. The costs in the present 
study were based on unit prices determined 
by following the microcosting method [11], 
while the costs in Lotan and Roehrborn 
[13] were according to the listing of the 
manufacturers. Another important difference 
between both studies is that in the present 
study at stage 3, 12 and 24 months there was 
a control cystoscopy in addition to MA urine 
analysis, which increased the costs.
Our Markov model did not explicitly account 
for the burden (i.e. quality of life, e.g. pain, 
infection rate) associated with cystoscopy. 
Cystoscopy would take place 7.6 times in the 
conventional arm and just 4.3 times in the 
test arm over the 2 years. However, we 
assumed that this difference is not enough 
to compensate for the more frequent 
cystectomies or greater risk of dying from 
cancer
 
.
 
 Further, in the test arm at stage 3, 12 
and 24 months MA urine analysis took place 
in addition to cystoscopy. Cystoscopy has by 
definition a high sensitivity. Therefore, at 
these stages the MA urine analyses might be 
superfluous and its costs can be saved here, 
i.e. in practice urologists should use MA as a 
substitute rather than as an adjunct for 
bladder cancer detection and follow-up. 
Another point is that MA blood analysis was 
required to provide reference values for MA 
urine analyses. The cost of MA blood analysis 
was incurred only once, at the start of 
surveillance. Over the course of, e.g. 10 years 
instead of 2 years of surveillance, there will 
hence be less difference in total costs 
between the arms.
Our study had some further limitations, 
primarily related to various assumptions that 
had to be made in the model to make the 
model manageable. For example, we assumed 
that progression only takes place after 
recurrence. However, it is conceivable that 
progression occurs directly from the health 
state ‘Well’. Based on data from the present 
study, we can assume that MA is more 
sensitive for progression than for recurrence. 
In all, this would make the cost-effectiveness 
for MA worse. Finally, it is not immediately 
clear how to exactly translate our cost 
estimates in other countries or clinical 
practice routines. The costs might vary from 
one area to another in Europe, and in the USA, 
and the panel of tested markers can be 
improved. Further prospective studies in a 
larger international population are therefore 
necessary.
Some recommendations can be made. The 
costs of MA (blood and urine analysis) were 
higher than the costs of cystoscopy. The large 
difference in cost is caused by material as well 
as personnel costs. Further automation of MA 
testing might lead to mass production and 
cost reduction. Research is needed to find out 
how much the cost per head will decrease due 
to automation. According to the model, the 
current MA markers were not sensitive 
enough compared with cystoscopy. Better MA 
markers should be found to obtain better 
cost-effectiveness. Sensitive markers of 
particular interest are those that do not 
require comparison with a blood sample of 
the patient for reference values. Notably, 
based on data from the present study, it is 
conceivable that awareness of a positive MA 
outcome might have prompted a higher 
detection rate of UC recurrences by 
cystoscopy. Indeed, separate analysis of the 
patients of the MA arm showed an improved 
cross-sectional sensitivity (70%) of the MA 
test [8]. Recent developments suggest other 
DNA-based tests as alternatives, such as 
detection of 
 
FGFR3
 
 mutations (present in 
most NMI-UC) and assays for detecting 
tumour-associated methylation of genes of 
interest [14–18], as these tests are cheaper 
than MA in material and personnel costs.
In conclusion, over the 2 years of surveillance 
in which cystoscopy was partly replaced by 
currently available urinary MA to reduce 
patient burden, it can only provide a cost-
effective alternative to conventional 
surveillance if the MA urine test had 
slightly better sensitivity and its costs were 
reduced.
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APPENDIX 1
Decision-analytic model for bladder cancer surveillance.
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